Low-dose tamoxifen halves recurrence of in situ breast cancer

The finding is practice-changing for women who are unable to tolerate the full dose, says researcher
Reuters Health
woman in pink bra with ribbon on strap denoting breast cancer

Tamoxifen at a low dose reduces local and contralateral recurrence of breast intraepithelial neoplasia, according to a new randomised controlled trial.

Italian researchers randomly assigned 500 women aged 75 or younger with in situ breast cancers to receive tamoxifen 5mg or placebo for three years after surgery.